Back to Search
Start Over
Design and Development of a Series of Potent and Selective Type II Inhibitors of CDK8
- Source :
- ACS medicinal chemistry letters. 7(6)
- Publication Year :
- 2016
-
Abstract
- Using Sorafenib as a starting point, a series of potent and selective inhibitors of CDK8 was developed. When cocrystallized with CDK8 and cyclin C, these compounds exhibit a Type-II (DMG-out) binding mode.
Details
- ISSN :
- 19485875
- Volume :
- 7
- Issue :
- 6
- Database :
- OpenAIRE
- Journal :
- ACS medicinal chemistry letters
- Accession number :
- edsair.doi.dedup.....8dbe04b31fbb281e1028cfa39678c3de